Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

East Hanover, New Jersey


Purpose:

This trial will assess whether RGH patients who have two recurrent episodes within a three month period would benefit from suppressive treatment and whether patients prefer episodic therapy or suppressive therapy for the treatment of their RGH.


Criteria:

Inclusion Criteria: - • Patients who are immunocompetent and who have had 4 or more episodes of Recurrent Genital Herpes (RGH) in the last 12 months. - Patients with active HSV-2 or HSV-1 infection as confirmed by Polymerase Chain Reaction (PCR). - Patients with active symptoms (i.e., itching, burning, tingling, aching, tenderness, rash or pain) associated with a recurrent episode of genital herpes Exclusion Criteria: - • Female patients who are pregnant or breast-feeding. - Current, history or suspicion of liver disease or kidney disease. - HIV infected (as confirmed by positive HIV serology). Other protocol-defined inclusion/exclusion criteria may apply.


NCT ID:

NCT00219310


Primary Contact:

Study Chair
Novartis Pharmaceuticals
Novartis Pharmaceuticals


Backup Contact:

N/A


Location Contact:

East Hanover, New Jersey
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.